A systematic evaluation of feature representations and transfer learning for cross-platform breast cancer subtyping

Cross-platform breast cancer subtyping remains challenging because performance can change across independent cohorts, assay platforms, preprocessing strategies, and label definitions. We benchmarked gene-level, pathway-level, PAM50, and a prespecified nine-module biological representation under strict cohort-disjoint transfer using 3897 patients from TCGA-BRCA, METABRIC, GSE20685, and GSE25066. Because label provenance can couple ground truth to evaluated features, inference was separated across reported-only labels, an externally-completed-label-excluded set treated as a partial procedural control, and a repeated disjoint-marker audit. Under reported-only labels, mean macro-AUROC was 0.949 for modules, 0.971 for genes, 0.973 for PAM50, and 0.961 for pathway rank scores; paired module-minus-gene and module-minus-PAM50 effects were − 0.022 and − 0.024. The frozen disjoint-marker audit retained 3768 of 3840 intended configurations (98.1%), comprising 1256 configurations per representation, and yielded module-minus-gene and module-minus-PAM50 differences of − 0.036 and − 0.039. In the externally-completed-label-excluded set, removing ESR1, PGR, and ERBB2 from the module definitions reduced module macro-AUROC from 0.936 to 0.928 (difference − 0.0087; 95% transfer-specification bootstrap CI − 0.0121 to − 0.0055), while depleted-module differences versus genes and PAM50 had confidence intervals spanning zero. After restricting every representation to nine ranked features, mean top-5 Jaccard was 0.774 for modules versus 0.229 for genes, 0.454 for PAM50, and 0.389 for pathways; corresponding RBO@9 values were 0.903, 0.281, 0.580, and 0.446. These dimension-matched metrics support attribution concentration and cross-transfer stability, not validated clinical interpretability. Overall, representation rankings depended on label provenance and marker overlap; biologically structured modules remained compact and attribution-stable but did not provide universally superior discrimination.

Authors

Institutions

Publication Details

Journal
Breast Cancer Research
Published
2026-10-31
DOI
https://doi.org/10.1186/s13058-026-02410-9
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A systematic evaluation of feature representations and transfer learning for cross-platform breast cancer subtyping

Tsung‐Rong Kuo, Po‐Jung Hsu, Ashutosh Tiwari, Radhakrishna Ramchandani et al.
Breast Cancer Research
Breast Cancer Treatment Studies
article

A systematic evaluation of feature representations and transfer learning for cross-platform breast cancer subtyping

Tsung‐Rong Kuo, Po‐Jung Hsu, Ashutosh Tiwari, Radhakrishna Ramchandani, Tsai-Mu Cheng
article en

Abstract

Cross-platform breast cancer subtyping remains challenging because performance can change across independent cohorts, assay platforms, preprocessing strategies, and label definitions. We benchmarked gene-level, pathway-level, PAM50, and a prespecified nine-module biological representation under strict cohort-disjoint transfer using 3897 patients from TCGA-BRCA, METABRIC, GSE20685, and GSE25066. Because label provenance can couple ground truth to evaluated features, inference was separated across reported-only labels, an externally-completed-label-excluded set treated as a partial procedural control, and a repeated disjoint-marker audit. Under reported-only labels, mean macro-AUROC was 0.949 for modules, 0.971 for genes, 0.973 for PAM50, and 0.961 for pathway rank scores; paired module-minus-gene and module-minus-PAM50 effects were − 0.022 and − 0.024. The frozen disjoint-marker audit retained 3768 of 3840 intended configurations (98.1%), comprising 1256 configurations per representation, and yielded module-minus-gene and module-minus-PAM50 differences of − 0.036 and − 0.039. In the externally-completed-label-excluded set, removing ESR1, PGR, and ERBB2 from the module definitions reduced module macro-AUROC from 0.936 to 0.928 (difference − 0.0087; 95% transfer-specification bootstrap CI − 0.0121 to − 0.0055), while depleted-module differences versus genes and PAM50 had confidence intervals spanning zero. After restricting every representation to nine ranked features, mean top-5 Jaccard was 0.774 for modules versus 0.229 for genes, 0.454 for PAM50, and 0.389 for pathways; corresponding RBO@9 values were 0.903, 0.281, 0.580, and 0.446. These dimension-matched metrics support attribution concentration and cross-transfer stability, not validated clinical interpretability. Overall, representation rankings depended on label provenance and marker overlap; biologically structured modules remained compact and attribution-stable but did not provide universally superior discrimination.

Breast Cancer Research
All India Institute of Medical Sciences Raipur (IN), Taipei Medical University Hospital (TW), Taipei Medical University-Shuang Ho Hospital (TW), Taipei Medical University (TW)
Openalex Percentile: Top 16%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon